BEACON EMR HIPAA Disclaimer Site Map Social Media
BayCare Health System
Community Benefit Financial Assistance Policy Quality Report Card Health Library News Dr.BayCare Find Us
Services Hospitals Find A Doctor Classes & Events About Us Careers Contact Us Get E-Newsletter
HealthDay Articles & Information
 Back  Back


May We Help You?
 

Call 1-877-692-2922
Monday-Friday, 8am to 5pm

Persons with hearing and speech disabilities can reach the above number through TDD and other specialized equipment by calling the Florida Relay Service at 711.

Contact Us
Send 
e-mail
Search jobs


Decrease (-) Restore Default Increase (+) Font Size
Print    Email
Search Health Information   

FDA Approves Drug for Older Women Experiencing Painful Sex

Osphena taken for 12 weeks found safe, effective in reducing discomfort

TUESDAY, Feb. 26 (HealthDay News) -- The U.S. Food and Drug Administration has approved a new drug to treat postmenopausal women who experience pain during sex, the agency announced Tuesday.

The drug Osphena (ospemifene) mimics the effects of estrogen on vaginal tissue, which can become thinner, drier and more fragile from menopause. The pill, taken with food once a day, makes vaginal tissue thicker and less fragile to reduce pain during sex (called dyspareunia).

"Dyspareunia is among the problems most frequently reported by postmenopausal women," said Dr. Victoria Kusiak, deputy director of the Office of Drug Evaluation III in the FDA's Center for Drug Evaluation and Research, in an FDA news release. "Osphena provides an additional treatment option for women seeking relief."

The safety and effectiveness of Osphena was established in three clinical studies involving nearly 1,900 postmenopausal women with signs of vulvar and vaginal atrophy, or thinning and fragile vaginal tissue.

Women were randomly assigned take either Osphena or a placebo. In the first two studies, those who took the drug for 12 weeks experienced significantly less pain during sex than the women in the placebo group.

Although a third study on Osphena found the drug is safe for long-term use, the FDA noted that the drug should be prescribed for the shortest duration needed.

Osphena can cause the lining of the uterus to thicken, which is abnormal for postmenopausal women, the FDA cautioned. Women should seek medical attention right away if they experience unusual bleeding since it could be a warning sign of uterine cancer.

The new drug can also increase women's risk for stroke and deep vein thrombosis, but not as much as estrogen-alone therapy, the FDA advised. Other possible Osphena side effects include hot flashes, vaginal discharge, muscle spasms, genital discharge and excessive sweating.

More information

The International Society for Gynecologic Endoscopy has more about pain during sex.


SOURCE: U.S. Food and Drug Administration, news release, Feb. 26, 2013

Health News Copyright © 2013 HealthDay. All rights reserved.


Serving The Tampa Bay Area © Copyright 2014 BayCare Health System